These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20346128)

  • 1. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.
    Bautista MA; Stevens WT; Chen CS; Curtis BR; Aster RH; Hsueh CT
    J Hematol Oncol; 2010 Mar; 3():12. PubMed ID: 20346128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report.
    Woo HS; Lee KH; Yoon PH; Kim SJ; Park I; Kim YS; Ahn HK; Hong J; Shin DB; Sym SJ
    Cancer Res Treat; 2015 Oct; 47(4):949-53. PubMed ID: 25544580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.
    Forcello NP; Khubchandani S; Patel SJ; Brahaj D
    J Oncol Pharm Pract; 2015 Apr; 21(2):148-56. PubMed ID: 24500808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report.
    Pietrantonio F; Di Bartolomeo M; Buzzoni R; Bajetta E
    Tumori; 2010; 96(1):154-6. PubMed ID: 20437874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin-induced acute thrombocytopenia: a case report and review of the literature.
    Suzuki K; Oda H; Sugawara Y; Masuya M; Nakase K; Fujioka M; Imai H; Katayama N
    Intern Med; 2013; 52(5):611-5. PubMed ID: 23448774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
    Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?
    James E; Podoltsev N; Salehi E; Curtis BR; Saif MW
    Clin Colorectal Cancer; 2009 Oct; 8(4):220-4. PubMed ID: 19822513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.
    Vyskocil J; Tucek S; Kiss I; Fedorova L; Nevrlka J; Zdrazilova-Dubska L
    Int Immunopharmacol; 2019 Sep; 74():105728. PubMed ID: 31288153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin immune-mediated thrombocytopenia: Is there a role for premedication or desensitization?
    Gal S; Noa M; Ofer M; Naama H; Ben B; Einat SS
    Br J Clin Pharmacol; 2022 Feb; 88(2):842-845. PubMed ID: 34237795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches.
    Bano N; Najam R; Qazi F; Mateen A
    Asian Pac J Cancer Prev; 2016; 17(4):1637-41. PubMed ID: 27221832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
    Mori Y; Nishimura T; Kitano T; Yoshimura K; Matsumoto S; Kanai M; Hazama M; Ishiguro H; Nagayama S; Yanagihara K; Teramukai S; Chiba T; Sakai Y; Fukushima M
    Oncology; 2010; 79(1-2):136-43. PubMed ID: 21150228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed hypersensitivity to oxaliplatin in a nigerian patient with colorectal cancer-A case report.
    Aliyu UM; Okwonna CO
    J Oncol Pharm Pract; 2021 Jul; 27(5):1258-1260. PubMed ID: 33131450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity reactions to oxaliplatin: experience in a single institute.
    Siu SW; Chan RT; Au GK
    Ann Oncol; 2006 Feb; 17(2):259-61. PubMed ID: 16282245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variant hypersensitivity reaction (HSR) presented with persistent dry cough after receiving oxaliplatin in a pancreatic cancer patient.
    Li J; Peccerillo J; Kaley K; Saif MW
    Iran J Allergy Asthma Immunol; 2009 Sep; 8(3):165-8. PubMed ID: 20124609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
    Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
    Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
    Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
    Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia.
    Dior M; Coriat R; Mir O; Brezault C; Perkins G; Dhooge M; Goldwasser F; Chaussade S
    Am J Med; 2012 Aug; 125(8):828-30. PubMed ID: 22840668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?
    Elligers KT; Davies M; Sanchis D; Ferencz T; Saif MW
    JOP; 2008 Mar; 9(2):197-202. PubMed ID: 18326929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication.
    Lee MY; Yang MH; Liu JH; Yen CC; Lin PC; Teng HW; Wang WS; Chiou TJ; Chen PM
    Support Care Cancer; 2007 Jan; 15(1):89-93. PubMed ID: 16865410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
    Park SJ; Lee KY; Park WS; Min SY
    Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.